Differences in chlorzoxazone metabolism in full mature male and female Sprague-Dawley rat, Beagle dog and Cynomolgus monkey liver

Human and Experimental Toxicology

Volumn 19, Issue 2, 2000, Pages 122-125

  Tanaka, E ^a   Shimamoto, A ^a   Nakamura, T ^a   Terao, K ^b   Misawa, S ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Cytochrome P450; Dog; Hepatic metabolism; Monkey; Rat; Sex difference

Indexed keywords

CHLORZOXAZONE; CYTOCHROME P450; DIMETHYLNITROSAMINE DEMETHYLASE; LIVER ENZYME; MUSCLE RELAXANT AGENT;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DOG; DRUG HYDROXYLATION; DRUG METABOLISM; FEMALE; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEX DIFFERENCE; SPECIES DIFFERENCE;

ANIMALIA; CANIS FAMILIARIS; MACACA FASCICULARIS;

EID: 0034108935     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/096032700678815738     Document Type: Article

References (37)

1. Foy BD, Toxopeus C, Frazier JM. Kinetic modeling of slow dissociation of bromosulphophthalein from albumin in perfused rat liver: toxicological implications. Toxicological Science 1999; 50: 20-29.
2. Rosenkranz HS et al. Development, characterization and application of predictive-toxicology models, SAR QSAR Environmental Reseach 1999; 10: 277-298.
3. Haddad S, Tardif R, Viau C, Krishnan K. A modeling approach to account for toxicokinetic interactions in the calculation of biological hazard index for chemical mixtures. Toxicological Letter 1999; 108: 303-308.
4. Brinkworth MH, Anderson D. An evaluation of two animal models for dietary influences on reproductive toxicology. In Vivo 1991; 5: 153-157.
5. Morgan LR et al. Comparative preclinical toxicology and pharmacology of 4,4′-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) in vitro and in rodents and primates. In Vivo 1997; 11; 29-37.
6. Peter R et al. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chemical Research in Toxicology 1990; 3: 566-573.
7. Vesell ES, Seaton TD, A-Rahim YI. Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe. Pharmacogenetics 1995; 5: 53-57.
8. Bachmann K, Sarver JG. Chlorzoxazone as a single sample probe of hepatic CYP2E1 activity in humans. Pharmacology 1996; 52: 169-177.
9. Koop DR. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB Journal 1992; 6: 724-730.
10. Raucy JL. Risk assessment: toxicity from chemical exposure resulting from enhanced expression of CYP2E1. Toxicology 1995; 105; 217-224.
11. Song BJ. Ethanol-inducible cytochrome P450 (CYP2E1): biochemistry, molecular biology and clinical relevance: 1996 up-date. Alcoholism, Clinical and Experimental Research 1996; 20: 138A-146A.
12. Raucy JL, Lasker JM, Lieber CS, Black M. Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Archives of Biochemistry & Biophysics 1989; 271: 270-283.
13. Spracklin DK et al. Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. Journal of Pharmacology & Experimental Therapeutics 1997; 281: 400-411.
14. Kharasch ED, Thummel KE, Mautz D, Bosse S. Clinical enflurane metabolism by cytochrome P450 2E1. Clinical Pharmacology & Therapeutics 1994; 55: 434-440.
15. Kharasch ED, Thummel KE. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology 1993; 79: 795-807.
16. Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. Journal of Clinical Pharmacy & Therapeutics 1998; 23: 247-255.
17. Hakkola J, Tanaka E, Pelkonen O. Developmental expression of cytochrome P450 enzymes in human liver. Pharmacology & Toxicology 1998; 82: 209-217.
18. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. Journal of Clinical Pharmacy & Therapeutics 1999; 24: 339-346.
19. Ono S et al. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 1995; 5: 143-150.
20. Imai Y, Ito A, Sato R. Evidence for biochemically different type of vesicles in the hepatic microsomal function. Journal of Biochemistry 1996; 60: 417-438.
21. Prough RA, Ziegler DM. The relative participation of liver microsomal amine oxidase and cytochrome P-450 in N-demethylation reactions. Archives of Biochemistry & Biophysics 1977; 180: 363-373.
22. Omura T, Sato R. The carbon monoxide binding pigment of liver microsomes, I. Evidence for its hemoprotoin nature. Journal of Biological Chemistry 1964; 239: 2370-2378.
23. Guengerich FP, Wang P, Davidson NK. Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biochemistry 1982; 21: 1698-1706.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. Journal of Biological Chemistry 1951; 193: 265-275.
25. Girre C et al. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochemical Pharmacology 1994; 47: 1503-1508.
26. Raucy JL et al. Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity. Drug Metabolism & Disposition 1997; 25: 1429-1435.
27. Dilger K, Metzler J, Bode JC, Klotz U. CYP2E1 activity in patients with alcoholic liver disease. Journal of Hepatology 1997; 27: 1009-1014.
28. Mishin VM et al. Chlorzoxazone pharmacokinetics as a marker of hepatic cytochrome P4502E1 in humans. American Journal of Gastroenterology 1998: 93: 2154-2161.
29. Lucas D et al. Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundamental & Clinical Pharmacology 1998; 12: 553-558.
30. McCarver DG et al. A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicology and Applied Pharmacology 1998; 152: 276-281.
31. Shimada T et al. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Archives of Toxicology 1997; 71: 401-408.
32. Amato G, Longo V, Mazzaccaro A, Gervasi PG. Chlorzoxazone 6-hydroxylase and p-nitrophenol hydroxylase as the most suitable activities for assaying cytochrome P450 2E1 in cynomolgus monkey liver. Drug Metabolism & Disposition 1998; 26: 483-489.
33. Shapiro BH, Agrawal AK, Pampori NA. Gender differences in drug metabolism regulated by growth hormone. International Journal of Biochemistry & Cell Biology, 1995; 27: 9-20.
34. Kato R, Yamazoe Y. Sex-specific cytochrome P450 as a cause of sex- and species-related differences in drug toxicity. Toxicology Letters 1992; 64-65: 661-667.
35. Imaoka S, Fujita S, Funae Y. Age-dependent expression of cytochrome P-450s in rat liver. Biochimica et Biophysica Acta 1991; 1097: 187-192.
36. Chengelis CP. Age- and sex-related changes in the components of the hepatic microsomal mixed function oxidase system in Sprague-Dawley rats. Xenobiotica 1988; 18: 1211-1224.
37. Fujita S et al. Alteration of plasma sex hormone levels associated with old age and its effect on hepatic drug metabolism in rats. Journal of Pharmacology & Experimental Therapeutics 1990; 253: 369-374.